Page 238 - 2021_07-Haematologica-web

Letters to the Editor
ma. MAbs. 2015;7(2):311-321.
7.Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic
CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking. J Immunol. 2016; 197(3):807-813.
8. Adams HC 3rd, Stevenaert F, Krejcik J, et al. High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune mod- ulation as a novel mechanism of action. Cytometry A. 2019;95(3):279-289.
9. Jiang H, Acharya C, An G, et al. SAR650984 directly induces mul- tiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30(2):399-408.
10. Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176-3187.
11. Rojkjaer L, Boxhammer R, Endell J, Winderlich M, Samuelsson C, MORPHOSYS AG. (2011) WO2012/041800. Anti-CD38 anti- body and lenalidomide or bortezomib for the treatment of mul-
tiple myeloma and NHL. Available from: https:// patentscope.wipo.int/search/en/detail.jsf?docId=WO2012041800 &recNum=5&office=&queryString=WO2012%2F041800+%28 MOR03087%29&prevFilter=&sortOption=Pub+Date+Desc&ma xRec=5. Accessed in June, 2020.
12. Elias KA, Landes G, Singh S, et al. (2012). WO2012/092612. Anti- CD38 antibodies. Available from: https://patentscope.wipo.int/ search/en/detail.jsf?docId=WO2012092612&recNum=113&doc An=US2011068235&queryString=%20&. Accessed in June, 2020.
13. Nijhof IS, Casneuf T, van Velzen JF, et al. CD38 expression and complement inhibitors affect response and resistance to daratu- mumab therapy in myeloma. Blood. 2016;128(7):959-970.
14. Krejcik J, Frerichs KA, Nijhof IS, et al. Monocytes and granulo- cytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab. Clin Cancer Res. 2017;23(24):7498- 7511.
15. Malavasi F, Faini AC. Mechanism of action of a new anti-CD38 antibody: enhancing myeloma immunotherapy. Clin Cancer Res. 2019; 25(10):2946-2948.
2008
haematologica | 2021; 106(7)